查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1573666

癌症切片市场、机会、成长动力、产业趋势分析与预测，2024-2032

Cancer Biopsy Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 205 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023 年，全球癌症活检市场价值为215 亿美元，预计2024 年至2032 年复合年增长率为8.4%。 。

液体活检和次世代定序 (NGS) 等技术因其精确性和微创方法而受到关注。这些进步正在彻底改变癌症诊断，为疾病检测和监测提供侵入性较小、更准确的方法。美国国家癌症研究所 (NCI) 2019 年的一份报告强调，液体活检可以检测超过 70% 的晚期癌症病例的基因突变，旨在加强早期检测、制定治疗策略并改善患者预后。

人们对遗传性肿瘤疾病和基因检测重要性的认识不断提高，需求不断扩大。这些技术有助于早期检测和个人化治疗，进而改善患者的治疗效果。因此，人们明显关注利用先进活检技术的见解进行标靶癌症治疗。

整个癌症活检行业根据活检类型、产品和服务、癌症类型、最终用户和地区进行分类。

组织活检领域预计在预测期内将以 8.3% 的复合年增长率成长，包括针吸活检、手术活检和其他组织类型。其市场主导地位源自于其作为癌症诊断黄金标准的地位，提供高度准确和可靠的结果。组织活检提供深入的组织学和分子见解，对于精确的肿瘤表征和后续治疗决策至关重要。它们的可靠性涵盖了各种癌症，包括乳腺癌、肺癌和前列腺癌，微创技术和影像技术的进步提高了精确度和安全性，这增强了它们的可靠性。

乳癌领域的需求激增，预计到 2032 年将达到 87 亿美元。 NCI 的数据表明，从2013 年到2018 年，乳癌发病率每年稳步上升0.5%，预计到2023 年将新增297,790 例乳癌病例。治疗方面进步的迫切需要，从而刺激了需求用于活检。此外，先进活检技术的可靠研究和临床证据扩大了该领域的需求，强调了其在解决全球乳癌负担方面的重要性。

亚太地区癌症活检市场预计将迅速扩张，到 2032 年复合年增长率将达到 8.7%。这一趋势推动了对先进活检技术的需求，这些技术有望实现精确诊断和有效治疗。此外，在政府措施和医疗保健投资的支持下，该地区尖端活检技术的可近性增强是该市场成长的重要推动力。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 癌症盛行率上升
      • 癌症切片技术的技术进步
      • 对遗传性肿瘤疾病和基因检测的认识不断提高
      • 扩大研发
    • 产业陷阱与挑战
      • 切片设备成本高
      • 严格的监管要求
  • 成长潜力分析
  • 技术景观
  • 未来市场趋势
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按活检类型，2021 - 2032 年

  • 主要趋势
  • 组织切片
    • 针吸切片
    • 手术切片
    • 其他组织切片类型
  • 液体活检
    • 循环肿瘤细胞 (CTC)
    • 循环肿瘤 DNA (ctDNA)
    • 其他液体活检类型
  • 影像引导活检
  • 其他活检类型

第 6 章：市场估计与预测：按产品和服务分类，2021 - 2032 年

  • 主要趋势
  • 产品
    • 切片针/枪
      • 细针穿刺切片检查 (FNA)
      • 空心针切片检查 (CNB)
      • 真空辅助切片装置
    • 切片钳
      • 普通活检钳
      • 热活检钳
    • 试剂盒和试剂
    • 耗材
  • 服务

第 7 章：市场估计与预测：按癌症类型，2021 - 2032 年

  • 主要趋势
  • 乳癌
  • 大肠直肠癌
  • 胃癌
  • 肺癌
  • 肝癌
  • 摄护腺癌
  • 卵巢癌
  • 其他癌症类型

第 8 章：市场估计与预测：按最终用户分类，2021 - 2032 年

  • 主要趋势
  • 医院
  • 癌症研究中心
  • 诊断中心
  • 研究与学术

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 10 章：公司简介

  • ANGLE plc.
  • BD (Becton, Dickinson and Company)
  • Biodesix (Integrated Diagnostics)
  • Chronix Biomedical, Inc (Oncocyte Corporation )
  • Devicor Medical Products, Inc.
  • GRAIL, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • IZI Medical Products
  • Lucence Health Inc.
  • Myriad Genetics, Inc.
  • Oncimmune Holdings PLC
  • Personal Genome Diagnostics Inc.
  • QIAGEN N.V.
简介目录
Product Code: 10995

The Global Cancer Biopsy Market was valued at USD 21.5 billion in 2023 and is projected to expand at a CAGR of 8.4% from 2024 to 2032. This growth is fueled by the rising prevalence of cancer and advancements in diagnostic technologies, particularly biopsies.

Techniques like liquid biopsy and next-generation sequencing (NGS) are gaining traction for their precision and minimally invasive approach. These advancements are revolutionizing cancer diagnostics, offering methods that are both less invasive and more accurate for disease detection and monitoring. A 2019 report from the National Cancer Institute (NCI) highlighted that liquid biopsies could detect genetic mutations in over 70% of advanced cancer cases, aiming to bolster early detection, tailor treatment strategies, and enhance patient outcomes.

Heightened awareness of inherited oncology disorders and the significance of genetic testing is amplifying demand. These technologies facilitate early detection and personalized treatments, leading to better patient outcomes. Consequently, there's a pronounced focus on targeted cancer therapies, harnessing insights from advanced biopsy techniques.

The overall cancer biopsy industry is classified based on biopsy type, product and services, cancer type, end-user, and region.

The tissue biopsy segment, projected to grow at a CAGR of 8.3% during the forecast period, encompasses needle biopsies, surgical biopsies, and other tissue types. Its market dominance stems from its status as the gold standard in cancer diagnosis, delivering highly accurate and dependable results. Tissue biopsies provide in-depth histological and molecular insights, crucial for precise tumor characterization and subsequent treatment decisions. Their reliability spans various cancers, including breast, lung, and prostate, bolstered by advancements in minimally invasive techniques and imaging technologies that enhance both precision and safety.

The breast cancer segment is witnessing surging demand, predicted to hit USD 8.7 billion by 2032. The global uptick in breast cancer cases underscores the pivotal role of biopsies in its management. Data from the NCI indicates a steady 0.5% annual rise in breast cancer incidence from 2013 to 2018, culminating in an estimated 297,790 new cases in 2023. This escalating prevalence accentuates the pressing need for advancements in detection, diagnosis, and treatment, fueling the demand for biopsies. Furthermore, robust research and clinical evidence for advanced biopsy techniques amplify their demand in this segment, underscoring its significance in tackling the global breast cancer burden.

Asia Pacific cancer biopsy market is set for swift expansion, with a CAGR of 8.7% through 2032. The region's growing embrace of genetic testing underscores the vital need for timely and accurate cancer detection. This trend propels the demand for advanced biopsy techniques, which promise precise diagnoses and effective treatments. Additionally, bolstered by government initiatives and healthcare investments, the region's enhanced accessibility to cutting-edge biopsy technologies is a significant driver of this market growth.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of cancer
      • 3.2.1.2 Technological advancements in cancer biopsy techniques
      • 3.2.1.3 Rising awareness in inherited oncology disorders and genetic testing
      • 3.2.1.4 Expansion of research and development
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of biopsy devices
      • 3.2.2.2 Stringent regulatory requirements
  • 3.3 Growth potential analysis
  • 3.4 Technology landscape
  • 3.5 Future market trends
  • 3.6 Regulatory landscape
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Biopsy Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Tissue biopsy
    • 5.2.1 Needle biopsy
    • 5.2.2 Surgical biopsy
    • 5.2.3 Other tissue biopsy types
  • 5.3 Liquid biopsy
    • 5.3.1 Circulating tumor cells (CTCs)
    • 5.3.2 Circulating tumor DNA (ctDNA)
    • 5.3.3 Other liquid biopsy types
  • 5.4 Image-guided biopsy
  • 5.5 Other biopsy types

Chapter 6 Market Estimates and Forecast, By Products and Services, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Products
    • 6.2.1 Biopsy needles/ guns
      • 6.2.1.1 Fine needle aspiration (FNA)
      • 6.2.1.2 Core needle biopsy (CNB)
      • 6.2.1.3 Vacuum-assisted biopsy devices
    • 6.2.2 Biopsy forceps
      • 6.2.2.1 General biopsy forceps
      • 6.2.2.2 Hot biopsy forceps
    • 6.2.3 Kits and reagents
    • 6.2.4 Consumables
  • 6.3 Services

Chapter 7 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Breast cancer
  • 7.3 Colorectal cancer
  • 7.4 Stomach cancer
  • 7.5 Lung cancer
  • 7.6 Liver cancer
  • 7.7 Prostate cancer
  • 7.8 Ovarian cancer
  • 7.9 Other cancer types

Chapter 8 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Cancer research centers
  • 8.4 Diagnostic centers
  • 8.5 Research and academics

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 ANGLE plc.
  • 10.2 BD (Becton, Dickinson and Company)
  • 10.3 Biodesix (Integrated Diagnostics)
  • 10.4 Chronix Biomedical, Inc (Oncocyte Corporation )
  • 10.5 Devicor Medical Products, Inc.
  • 10.6 GRAIL, Inc.
  • 10.7 Hologic, Inc.
  • 10.8 Illumina, Inc.
  • 10.9 IZI Medical Products
  • 10.10 Lucence Health Inc.
  • 10.11 Myriad Genetics, Inc.
  • 10.12 Oncimmune Holdings PLC
  • 10.13 Personal Genome Diagnostics Inc.
  • 10.14 QIAGEN N.V.